Bristol Myers Squibb’s CAR-T therapy Breyanzi has become the first such treatment approved for patients with a rare, slow-growing type of non-Hodgkin lymphoma.
The drug was approved Thursday for third-line patients with marginal zone lymphoma ...
↧